title: Reply to N. Singh et al.
authors.forename: Maurice
authors.initials: M
authors.lastname: Pérol
authors.forename: David
authors.initials: D
authors.lastname: Pérol
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaid
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D060046:Maintenance Chemotherapy; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D002945:Cisplatin